[1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. DOI: 10.1056/NEJMoa02026510.1056/NEJMoa020265]Open DOISearch in Google Scholar
[2. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4(3):361-71. DOI: 10.1016/S1388-9842(01)00198-210.1016/S1388-9842(01)00198-2]Open DOISearch in Google Scholar
[3. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J. 2004;25(4):300-7. DOI: 10.1016/j.ehj.2003.12.01210.1016/j.ehj.2003.12.01214984918]Open DOISearch in Google Scholar
[4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46. DOI: 10.1136/hrt.2003.02527010.1136/hrt.2003.025270195504017699180]Open DOISearch in Google Scholar
[5. Tavazzi L, Senni M, Metra M, Gorini M, Cacciatore G, Chinaglia A, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6(3):473-81. DOI: 10.1161/CIRCHEARTFAILURE.112.00016110.1161/CIRCHEARTFAILURE.112.00016123476054]Open DOISearch in Google Scholar
[6. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESCHF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613-25. DOI: 10.1002/ejhf.56610.1002/ejhf.56627324686]Open DOISearch in Google Scholar
[7. Hamo CE, Butler J, Gheoghiade M, Chioncel O. The bumpy road to drug development for acute heart failure. European Heart Journal Supplements. 2016;18(suppl_G, 1 November 2016):G19–G32.10.1093/eurheartj/suw045]Search in Google Scholar
[8. O’Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159(5):841-9 e1.10.1016/j.ahj.2010.02.02320435194]Search in Google Scholar
[9. Antohi EL, Dobreanu D, Deleanu D, Tatu-Chitoiu G, Macarie C, Chioncel O. Relation between non-cardiac comorbidities and use of evidence based therapies in patients with in-hospital heart failure-data from SONIC-RO study. Eur J Heart Fail Suppl. 2013;12:S354-S80.]Search in Google Scholar
[10. Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, et al. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur Heart J. 2017;38(5):362-72.10.1093/eurheartj/ehw333]Search in Google Scholar
[11. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786-95. DOI: 10.1002/ejhf.47310.1002/ejhf.47326821594]Open DOISearch in Google Scholar
[12. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52(7):501-11. DOI: 10.1016/j.jacc.2008.04.04410.1016/j.jacc.2008.04.04418687241]Open DOISearch in Google Scholar
[13. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1 Suppl 1:S4-8. DOI: 10.2215/CJN.0149050610.2215/CJN.0149050617699374]Open DOISearch in Google Scholar
[14. Ponikowski P, Voors AA, Anker SD, Bueno H, Cle-land JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. DOI: 10.1093/eurheartj/ehw12810.1093/eurheartj/ehw12827206819]Open DOISearch in Google Scholar
[15. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141-9. DOI: 10.1093/ndt/gfg49310.1093/ndt/gfg49314671049]Open DOISearch in Google Scholar
[16. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-43. DOI: 10.1016/j.bbamcr.2012.01.01410.1016/j.bbamcr.2012.01.014404885622306005]Open DOISearch in Google Scholar
[17. Feelders RA, Kuiper-Kramer EP, van Eijk HG. Structure, function and clinical significance of transferrin receptors. Clin Chem Lab Med. 1999;37(1):1-10. DOI: 10.1515/CCLM.1999.00110.1515/CCLM.1999.00110094372]Open DOISearch in Google Scholar
[18. Divakaran V, Mehta S, Yao D, Hassan S, Simpson S, Wiegerinck E, et al. Hepcidin in anemia of chronic heart failure. Am J Hematol. 2011;86(1):107-9. DOI: 10.1002/ajh.2190210.1002/ajh.21902307600421080339]Open DOISearch in Google Scholar
[19. Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, et al. High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail. 2014;16(9):984-91. DOI: 10.1002/ejhf.13910.1002/ejhf.13925065368]Open DOISearch in Google Scholar
[20. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-7. DOI: 10.1161/CIRCULATION-AHA.107.69690610.1161/-AHA.107.696906]Open DOISearch in Google Scholar
[21. Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM, Johnson AE, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178-87. DOI: 10.7326/0003-4819-150-3-200902030-0000710.7326/0003-4819-150-3-200902030-00007273859219189907]Open DOISearch in Google Scholar
[22. Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, et al. Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010;3(1):97-103. DOI: 10.1161/CIRCHEARTFAILURE.109.88521010.1161/CIRCHEARTFAILURE.109.885210283081119903931]Open DOISearch in Google Scholar
[23. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355-63. DOI: 10.1001/jama.2012.21647610.1001/jama.2012.216476368808323340637]Open DOISearch in Google Scholar
[24. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245. DOI: 10.1161/CIR.0b013e31828124ad10.1161/CIR.0b013e31828124ad540851123239837]Open DOISearch in Google Scholar
[25. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5-37.]Search in Google Scholar
[26. Chioncel O, Vinereanu D, Datcu M, Ionescu DD, Capalneanu R, Brukner I, et al. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J. 2011;162(1):142-53 e1.10.1016/j.ahj.2011.03.03321742101]Search in Google Scholar
[27. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210-9. DOI: 10.1056/NEJMoa121486510.1056/NEJMoa121486523473338]Open DOISearch in Google Scholar
[28. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48. DOI: 10.1056/NEJMoa090835510.1056/NEJMoa090835519920054]Open DOISearch in Google Scholar
[29. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015;36(11):657-68. DOI: 10.1093/eurheartj/ehu38510.1093/eurheartj/ehu385435935925176939]Open DOISearch in Google Scholar
[30. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241-51. DOI: 10.1016/j.jacc.2011.04.04010.1016/j.jacc.2011.04.04021903058]Open DOISearch in Google Scholar
[31. Brownlie Tt, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr. 2004;79(3):437-43. DOI: 10.1093/ajcn/79.3.43710.1093/ajcn/79.3.43714985219]Open DOISearch in Google Scholar
[32. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872-80. DOI: 10.1093/eurheartj/ehq15810.1093/eurheartj/ehq15820570952]Open DOISearch in Google Scholar
[33. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899-906. DOI: 10.1016/j.cardfail.2011.08.00310.1016/j.cardfail.2011.08.00322041326]Open DOISearch in Google Scholar
[34. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling US adults with self-reported heart failure in the National Health and Nutrition Examination Survey III: prevalence and associations with anemia and inflammation. Circ Heart Fail. 2011;4(5):599-606. DOI: 10.1161/CIRCHEARTFAILURE.111.96090610.1161/CIRCHEARTFAILURE.111.960906318090321705484]Open DOISearch in Google Scholar
[35. Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol. 1997;79(2):120-7. DOI: 10.1016/S0002-9149(96)00697-210.1016/S0002-9149(96)00697-2]Open DOISearch in Google Scholar
[36. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326(7399):1124. DOI: 10.1136/bmj.326.7399.112410.1136/bmj.326.7399.1124]Open DOISearch in Google Scholar
[37. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18(2):319-32. DOI: 10.1016/j.beha.2004.08.02210.1016/j.beha.2004.08.022]Open DOISearch in Google Scholar
[38. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011;86(11):923-7. DOI: 10.1002/ajh.2210810.1002/ajh.22108]Open DOISearch in Google Scholar
[39. Beguin Y. The soluble transferrin receptor: biological aspects and clinical usefulness as quantitative measure of erythropoiesis. Haematologica. 1992;77(1):1-10.]Search in Google Scholar
[40. Cotton F, Thiry P, Boeynaems J. Measurement of soluble transferrin receptor by immunoturbidimetry and immunonephelometry. Clin Biochem. 2000;33(4):263-7. DOI: 10.1016/S0009-9120(00)00071-010.1016/S0009-9120(00)00071-0]Open DOISearch in Google Scholar
[41. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811-9. DOI: 10.1074/jbc.M00892320010.1074/jbc.008923200]Open DOISearch in Google Scholar
[42. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-8. DOI: 10.1182/blood-2003-03-067210.1182/blood-2003-03-067212663437]Search in Google Scholar
[43. Diwan A, Tran T, Misra A, Mann DL. Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med. 2003;3(2):161-82. DOI: 10.2174/156652403336153710.2174/156652403336153712630562]Open DOISearch in Google Scholar
[44. Konstam MA, Gheorghiade M, Burnett JC, Jr., Grin-feld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319-31. DOI: 10.1001/jama.297.12.131910.1001/jama.297.12.131917384437]Open DOISearch in Google Scholar
[45. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdis-charge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-35. DOI: 10.1001/jama.2013.195410.1001/jama.2013.195423478743]Open DOISearch in Google Scholar